Literature DB >> 19942822

Liraglutide: a once-daily human glucagon-like peptide-1 analogue.

G Aimaretti1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19942822     DOI： 10.1007/BF03345744

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  19 in total

1.  The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro.

Authors:  Søren Bregenholt; Annette Møldrup; Niels Blume; Allan E Karlsen; Birgitte Nissen Friedrichsen; Ditte Tornhave; Lotte Bjerre Knudsen; Jacob S Petersen
Journal:  Biochem Biophys Res Commun       Date:  2005-05-06       Impact factor: 3.575

2.  Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes.

Authors:  Tina Vilsbøll; Milan Zdravkovic; Tu Le-Thi; Thure Krarup; Ole Schmitz; Jean-Pierre Courrèges; Robert Verhoeven; Ingrid Bugánová; Sten Madsbad
Journal:  Diabetes Care       Date:  2007-03-19       Impact factor: 19.112

3.  The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

Authors:  H Agersø; L B Jensen; B Elbrønd; P Rolan; M Zdravkovic
Journal:  Diabetologia       Date:  2002-02       Impact factor: 10.122

4.  NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs.

Authors:  Ulla Ribel; Marianne O Larsen; Bidda Rolin; Richard D Carr; Michael Wilken; Jeppe Sturis; Lisbet Westergaard; Carolyn F Deacon; Lotte Bjerre Knudsen
Journal:  Eur J Pharmacol       Date:  2002-09-13       Impact factor: 4.432

5.  One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

Authors:  Kristine B Degn; Claus B Juhl; Jeppe Sturis; Grethe Jakobsen; Birgitte Brock; Visvanathan Chandramouli; Joergen Rungby; Bernard R Landau; Ole Schmitz
Journal:  Diabetes       Date:  2004-05       Impact factor: 9.461

6.  GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics.

Authors:  Jeppe Sturis; Carsten F Gotfredsen; John Rømer; Bidda Rolin; Ulla Ribel; Christian L Brand; Michael Wilken; Karsten Wassermann; Carolyn F Deacon; Richard D Carr; Lotte Bjerre Knudsen
Journal:  Br J Pharmacol       Date:  2003-07-29       Impact factor: 8.739

7.  Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia.

Authors:  J J Meier; B Gallwitz; N Siepmann; J J Holst; C F Deacon; W E Schmidt; M A Nauck
Journal:  Diabetologia       Date:  2003-05-23       Impact factor: 10.122

8.  The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice.

Authors:  Bidda Rolin; Marianne O Larsen; Carsten F Gotfredsen; Carolyn F Deacon; Richard D Carr; Michael Wilken; Lotte Bjerre Knudsen
Journal:  Am J Physiol Endocrinol Metab       Date:  2002-10       Impact factor: 4.310

9.  GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice.

Authors:  Mohammad Hossein Noyan-Ashraf; M Abdul Momen; Kiwon Ban; Al-Muktafi Sadi; Yu-Qing Zhou; Ali M Riazi; Laurie L Baggio; R Mark Henkelman; Mansoor Husain; Daniel J Drucker
Journal:  Diabetes       Date:  2009-01-16       Impact factor: 9.461

10.  Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.

Authors:  Michael Nauck; Anders Frid; Kjeld Hermansen; Nalini S Shah; Tsvetalina Tankova; Ismail H Mitha; Milan Zdravkovic; Maria Düring; David R Matthews
Journal:  Diabetes Care       Date:  2008-10-17       Impact factor: 17.152
View more
  3 in total

Review 1.  A Plethora of GLP-1 Agonists: Decisions About What to Use and When.

Authors:  Susan L Samson; Alan J Garber
Journal:  Curr Diab Rep       Date:  2016-12       Impact factor: 4.810

2.  One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study.

Authors:  Marco Zavattaro; Marina Caputo; Maria Teresa Samà; Chiara Mele; Luisa Chasseur; Paolo Marzullo; Loredana Pagano; Maria Grazia Mauri; Maria Chantal Ponziani; Gianluca Aimaretti; Flavia Prodam
Journal:  Endocrine       Date:  2015-01-09       Impact factor: 3.633

3.  Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus.

Authors:  Jason Seewoodhary; Leanne Griffin; Stephen C Bain
Journal:  Diabetes Metab Syndr Obes       Date:  2010-05-17       Impact factor: 3.168
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.